

CD276

Research Grade Enoblituzumab

Catalog No.	DHJ04001A DHJ04001B	Quantity:	100 µg 1.0 mg
Alternate Names:	MG-A271, CAS: 1353485-38-7		
Description:	Enoblituzumab is a humanized, Fc-engineered, B7-H3-targeting antibody that mediates antibody-dependent cellular cytotoxicity. CD276 antigen is a tumor-associated antigen and possible immune checkpoint, is highly expressed in prostate cancer (PCa) and is associated with early recurrence and metastasis.		
UniProt ID (target):	Q5ZPR3		
Target:	Human CD276 antigen		
Concentration:	1.0 mg/ml, lot specific		
Source:	XtenCHO		
Isotype:	Humanized IgG1 kappa		
Formulation:	0.01M PBS buffer, pH 7.4		
Purity:	> 95% by SDS-PAGE		
Endotoxin Level:	≤ 0.01 EU/µg by LAL analysis		
Purification:	Protein A/G affinity chromatography		
Biological Activity:	EC ₅₀ = 60.20 ng/ml, binding with CD276 by direct ELISA		
Applications:	Functional studies		
Storage & Stability:	Store at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

